← Back
Data updated: Mar 10, 2026
AVET
Infectious DiseaseDermatologyMetabolic
AVET is a specialty pharmaceutical company focused on Infectious Disease, Dermatology, Metabolic. Key products include DOXERCALCIFEROL.
1957
Since
2
Drugs
-
Trials
3
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
ACHROMYCIN V 2025-03-31
Labeling
DOXERCALCIFEROL 2025-03-14
Labeling
DOXERCALCIFEROL 2024-11-22
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 29%
1 drugs
Dermatology 29%
1 drugs
Metabolic 29%
1 drugs
Oncology 14%
0 drugs Phase 2: 1 Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
KING PHARMS LLC big-pharma
Infectious Disease, Dermatology, Oncology, Metabolic
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Baxter specialty
Infectious Disease, Oncology, Dermatology
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Metabolic
Active (2)
Discontinued (0)
Company Info
- First Approval
- 1957-10-08
- Latest
- 2025-03-31
- Applications
- 2